Literature DB >> 1270887

A new approach to quantitation of the various sources of bilrubin in man.

P D Berk, T F Blaschke, B F Scharschmidt, J G Waggoner, N I Berlin.   

Abstract

Studies of the "early labeling" of fecal bile pigment have been widely interpreted as indicating that 10 to 20 per cent of total bile pigment production in normal man is derived from the processes which give rise to the "early labeled" pigment peak (ELP). However, this conclusion is based on a very small number of studies with inherent experimental and analytic limitations. In the present study, a new experimental approach was employed. Plasma bilirubin turnover (BRT), total red blood cell volume (TRCV), and red cell survival were measured in 26 normal volunteers and 35 patients with various hepatic and/or hematologic disorders. The quantity of bilirubin derived from red blood cell degradation (BRRBC) was calculated from TRCV and the mean red cell life-span, and the difference between BRT and BRRBC, designated "excess bilirubin synthesis (EBS)," was considered to represent the quantity of bilirubin derived from the processes responsible for ELP. In normal volunteer subjects, EBS averaged 1.0 mg. per kilogram per day, and accounted for 25 per cent of daily bilirubin turnover. Hence, results derived by this approach exceeded the range estimated from analysis of "early labeled peak" data. Further analysis of the data in terms of a simple model of bilirubin sources was compatible with the hypothesis that EBS consists of an essentially constant component, averaging 0.8 mg. per kilogram per day, presumably derived principally from the liver, and a second component which varies with the erthropoietic rate. Hence, in normal man the liver may contribute the major fraction of EBS.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1270887

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  11 in total

Review 1.  Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome.

Authors:  Paul D Berk
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

Review 2.  Twenty-five years of progress in bilirubin metabolism (1952-77).

Authors:  B H Billing
Journal:  Gut       Date:  1978-06       Impact factor: 23.059

Review 3.  New insights into the classification and mechanisms of hereditary, chronic, non-haemolytic hyperbilirubinaemias.

Authors:  P Berthelot; D Dhumeaux
Journal:  Gut       Date:  1978-06       Impact factor: 23.059

4.  Role of ineffective erythropoiesis in anaemia of RA.

Authors:  I Cavill; C Ricketts
Journal:  Ann Rheum Dis       Date:  1977-12       Impact factor: 19.103

5.  Role of bilirubin overproduction in revealing Gilbert's syndrome: is dyserythropoiesis an important factor?

Authors:  J M Metreau; J Yvart; D Dhumeaux; P Berthelot
Journal:  Gut       Date:  1978-09       Impact factor: 23.059

Review 6.  Carbon monoxide detection and biological investigations.

Authors:  D K Stevenson; H J Vreman; R J Wong; P A Dennery; C H Contag
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

7.  Hepatic disposition and biliary excretion of bilirubin and bilirubin glucuronides in intact rats. Differential processing of pigments derived from intra- and extrahepatic sources.

Authors:  J M Crawford; B J Ransil; C S Potter; S V Westmoreland; J L Gollan
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

Review 8.  Gilbert's syndrome and drug metabolism.

Authors:  A F Macklon; R L Savage; M D Rawlins
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

9.  Congenital dyserythropoietic anaemia: response to splenectomy and quantitation of ineffective erythropoiesis.

Authors:  D Samson; D Halliday; I Chanarin
Journal:  J Clin Pathol       Date:  1977-02       Impact factor: 3.411

10.  Carboxyhemoglobin levels in medical intensive care patients: a retrospective, observational study.

Authors:  Andreas S Fazekas; Marlene Wewalka; Christian Zauner; Georg-Christian Funk
Journal:  Crit Care       Date:  2012-01-11       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.